Abstract 460P
Background
Cancer diagnosis and treatment can give rise to psychological challenges for patients. Amidst the adversity, there exists the potential for post-traumatic growth (PTG), a phenomenon characterized by positive psychological changes and personal development following traumatic experiences. Group-based interventions have emerged as a promising avenue for fostering PTG among individuals with cancer. This systematic review aims to assess the group-based interventions designed to facilitate PTG in cancer patients.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used were group-based intervention, group therapy, PTG, positive psychological change, and cancer. Publications were limited to English manuscripts published in the last 10 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review encompassed a selection of 12 studies, with 970 individuals aged above 18 years. The sampled patients displayed wide cancer types, including breast, gynaecologic, hematologic, head and neck, gastrointestinal, urological, and lymphoma. Group therapies in this review were mindfulness-based psychotherapy, cognitive behavioural stress management, acceptance and commitment therapy, supportive and positive group therapy, art and relaxation response resiliency mind-body program, varied from 5-12 sessions. The primary assessment tool is Post-Traumatic Growth Inventory (PTGI). The findings suggest that group interventions contribute to the personal strength, positive affect, and sense of meaning in cancer-related trauma. While positive trends were observed, the magnitude of PTG outcomes varied, likely influenced by duration, composition, and participant readiness for growth.
Conclusions
To conclude, this systematic review assesses the potential of group-based interventions as resource in promoting PTG among cancer patients. Nevertheless, the variations in outcomes across studies emphasize the need for interventions, accounting for individual differences. This review contributes to our understanding of the relationship between group-based interventions and PTG among cancer patients, paving the way for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. G. William.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract